i linda grant works for the american parcel miss foundation its mission is to bring research neglected by industry to market maturity male contraceptives for example our founder languorous na was very impressed with the work on rice which is a product that. is a device using a gel and actually emptying the rights to the outside. the cost ninety thousand euro's. vessel jail is a non-hormonal polymer gel that specifically blocks the vast difference and prevents sperm transportation for about ten years. the principle is comparable to sterilization but can be easily reversed because a second injection can just rinse the gel out again. it's been tested successfully on humans in india for years however the w.h.o. raised concerns and prevented western countries from participating in the study the foundation is now aiming to change that. that'll. get it to market. it's a horrible quality it. is not. the devil which zero estimates that there are eighty million and want to pregnancies every year but the development of contraceptive methods for men has stalled and not only because of male concern

grants interest from the n.i.h. starting in 2002. i later received supplemental funding from the bill and me linda gates foundation. other research was funded by c.d.c. and gates. the u.s. funded the majority, investing hundreds of millions of taxpayer dollars. scientists discovered that adding a drug increased protection and the combination of those two medications which is f.d.a. approved. also it was found that pre- exposure your dozing added substantially to protective events and it's these inventionings that led to c.d.r. patents awarded several years ago. gilead did not privement provide leadership or funding for prep research. their role was to providing placebos. ghim gill made public in twifewoy -- 2005 it would not seek f.d.a aprove for prep who -- no matter what the data showed. gilead took steps to limit research on alternative and competing prep agents. in particular, there was interest in 3 t.c., a competing drug, because it was on a -- about to go off patent. interest dissipated with assurances that gilead's truvada would be generally available by the time efficacy trials were completed. eight years